Artificial Intelligence and Hepatocellular Carcinoma

Launched by HUMANITAS CLINICAL AND RESEARCH CENTER · Dec 1, 2022

Keywords

ClinConnect Summary

This clinical trial is focused on finding new ways to identify patients with Hepatocellular Carcinoma (HCC), which is a type of liver cancer, and to better understand their risk of the cancer coming back after surgery. Researchers are using advanced computer techniques, including artificial intelligence, to analyze medical images and other data. They hope to discover important signs that can indicate how aggressive the cancer is and how well patients might do after their surgery.

To participate in this study, you need to be at least 18 years old and have a confirmed diagnosis of HCC. You should either be facing your first diagnosis or have had a recurrence of the disease that is being treated for the first time with surgery. Additionally, you must have had a special type of CT scan with contrast that was done within a month before your surgery. It's important to note that this trial is currently not recruiting new participants, but it is actively studying existing patients. If you’re considering participating in future trials or want to learn more about HCC, discussing your options with your healthcare provider can be a good next step.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age \>= 18 years old.
• • Hepatocarcinoma diagnosis confirmed at histological specimen
• • Being at the first HCC diagnosis or with a recurrence/persistence disease evaluated and treated for the first time with surgery at the participating center.
• • Available contrast-enhanced CT Scan obtained no more than 1 month prior to surgery.
• Exclusion Criteria:
• • Surgery as a downstaging therapy for transplant
• • Patients treated with surgery in case of not-curative intent (palliation, best supportive care, etc).
• • Histopathological specimen of combined liver primary neoplasms (e.g. 'epatocolangiocarcinoma').